Disseminated intravascular coagulopathy (DIC): Pathophysiology, laboratory diagnosis, and management

Journal of Intensive Care Medicine

Volumn 15, Issue 3, 2000, Pages 144-158

  Senno, Sandra L ^a   Pechet, Liberto ^a,c   Bick, Rodger L ^b  

^a University of Massachusetts   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c One Biotech Park   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTIBIOTIC AGENT; ANTIFIBRINOLYTIC AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; APROTININ; BLOOD CLOTTING FACTOR CONCENTRATE; D DIMER; DITHIOCARBAMIC ACID DERIVATIVE; FRESH FROZEN PLASMA; GABEXATE; HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; VITAMIN K GROUP;

CRYOPRECIPITATE; DISSEMINATED INTRAVASCULAR CLOTTING; HUMAN; HYPOFIBRINOGENEMIA; LABORATORY DIAGNOSIS; PARTIAL THROMBOPLASTIN TIME; PATHOGENESIS; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; SEPTIC SHOCK; THROMBIN TIME; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 0034024875     PISSN: 08850666     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1489.2000.00144.x     Document Type: Review

References (62)

1. Lasch HG, Heene DL, Huth IC, et al. Pathophysiology: clinical manifestations and therapy of consumptive coagulopathy. Am J Cardiol 1967;20:381-391
2. Bick R. Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations. Semin Thromb Hemost 1998;24:3-18
3. Gando S, Kameur T, Nanzaki E, et al. Cytokines. Soluble thrombomodulin and disseminated intravascular coagulation in patients with systemic inflammatory response syndrome. Thromb Res 1995;80:519-525
4. Okajima K, Uchiba M, Murakami K, et al. Plasma levels of soluble E-selectin in patients with disseminated intravascular coagulation. Am J Hematol 1997;54:219-224
5. Ishibashi M, Ito N, Fujita M, et al. Endothelin-1 as an aggravating factor of disseminated intravascular coagulation associated with malignant neoplasms. Cancer 1994;73:191-195
6. Verveloet M, Lambertus T, Hack E. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost 1998;24:33-44
7. Robson S, Shephard E, Kirsch R. Fibrin degradation product D-dimer induces the synthesis and release of biological active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 1994;86:322-326
8. Williams E. Disseminated intravascular coagulation. In: Loscalzo J, Schafer AL, eds. Thrombosis and hemorrhage, 2nd ed. Baltimore: Williams & Wilkins, 1998:963-985
9. Bick RL. Disseminated intravascular coagulation and related syndromes: a clinical review. Semin Thromb Hemost 1988; 14:299-338
10. Murano G, Williams L, Miller-Anderson MX, et al. Some properties of antithrombin-III and its concentration in human plasma. Thromb Res 1980;18:259-262
11. Mammen E. Antithrombin: its physiological importance and role in disseminated intravascular coagulation. Semin Thromb Hemost 1998;24:19-25
12. Rosenberg RD, Bauer KA. The heparin-antithrombin system: a natural anticoagulation mechanism. In: Colman RW, Hirsch J, Marder VJ, et al., eds. Hemostasis and thrombosis. Basic principles and clinical practice. Philadelphia: Lippincott, 1994:837-860
13. Weiss A. Acquired coagulation disorders. In: Corriveau DM, Fritsma GA, eds. Hemostasis and thrombosis in the clinical laboratory. Philadelphia: JB Lippincott, 1988:169-205
14. Limmie B, Tran TH, Ritz R, et al. Plasma prekallikren, factor XII, antithrombin III, C1-inhibitor and alpha 2-macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC). Am J Clin Pathol 1984;82: 396-404
15. Wilson RF, Mammen EF, Robson MC, et al. Antithrombin, prekallikren and fibronectin levels in surgical patients. Arch Surg 1986;121:635-640
16. Andrew M. Developmental hemostasis: relevance to hemostatic problems during childhood. Semin Thromb Hemost 1995;21:341-356
17. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992;326:800-806
18. Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991;66:6-15
19. Senno SL, Pechet L. Clinical implications of elevated PAI-1 revisited: multiple arterial thrombosis in a patient with essential thrombocythemia and elevated plasminogen inhibitor-1 (PAI-1) levels with a review of the literature. J Thromb Thrombol 1999;8:1-8
20. Jacobson RJ, Jackson DP. Erythrocyte fragmentation in defribination syndromes. Ann Intern Med 1974;81:207-209
21. Mammen EF. Perspectives for the future. Intensive Care Med 1993;19 (suppl 1):S29-S34
22. Stein SF, Harker LA. Kinetic and functional studies of platelets, fibrinogen and plasminogen in patients with hepatic cirrhosis. J Lab Clin Med 1982;99:217-230
23. Takahashi H, Tatewaki W, Wada K, et al. Thrombin and plasmin generation in patients with liver disease. Am J Hematol 1989;32:30-35
24. Hersch SL, Kunelis T, Francis RB Jr. The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor. Blood 1987;69:1315-1319
25. Berghans GM. Pathophysiologic and biochemical events in disseminated intravascular coagulation: dysregulation of procoagulant and anticoagulant pathways. Semin Thromb Hemost 1989;15:58
26. Rosenfeld KE, Gralnick HR. Hematologic-oncologic monitoring. In: Tobin MJ, ed. Principles and practice of intensive care monitoring. New York: McGraw-Hill, 1998:1133-1149
27. Penner J. Disseminated intravascular coagulation in patients with multiple organ failure of non-septic origin. Semin Thromb Hemost 1998;24:45-52
28. Wada H, Wakita Y, Nakase T, et al. Diagnosis of pre-disseminated intravascular coagulation stage with hemostatic molecular markers. Pol J Pharmacol 1996;48:225-228
29. Astiz ME, Rackaw EC. Septic shock. Lancet 1998;351: 1501-1505
30. Bruhn HD, Conard J, Manucci MP, et al. Multicentric evaluation of a new assay for prothrombin fragment F1 + 2 determination. Thromb Haemost 1992;68:413-417
31. Damas P, Canivet JL, de Groote D, et al. Sepsis and serum cytokine concentrations. Crit Care Med 1997;25:405-412
32. Spivak JL, Sprangler DB, Bell WR. Defribination after intraamniotic injections of hypertonic saline. N Engl J Med 1972; 287:321-323
33. Callander N, Rapaport SI. Trousseau's syndrome. West J Med 1993;158:364-371
34. Menell JS, Cesarman GM, Jacovina AT, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999;340:994-1004
35. Yu M, Nardella A, Pechet L. Screening tests of disseminated intravascular coagulation: guidelines for rapid and specific laboratory diagnosis. Crit Care Med (in press)
36. van de Water L, Carr JM, Aronson D, et al. Analysis of elevated fibrin(ogen) degradation products levels in patients with liver disease. Blood 1986;67:1468-1473
37. Hellgren M, Egberg N, Eklund J. Blood coagulation and fibrinolytic factors and their inhibitors in critically ill patients. Intensive Care Med 1984;10:23-29
38. Fourrier F, Chopin C, Goudemand J. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C and protein S deficiencies. Chest 1992;101:816-823
39. Kidokoro A, Iba T, Fukunaga M, et al. Alterations in coagulation and fibrinolysis during sepsis. Shock 1996;5:223-228
40. Takahashi H, Tatewaki W, Wada K, et al. Thrombin versus plasmin generation in disseminated intravascular coagulation associated with various underlying disorders. Am J Hematol 1990;33:90-95
41. de Jonge E, Levi M, Stoutenbeek CP, et al. Current drug treatment strategies for disseminated intravascular coagulation. Drugs 1998;55:767-777
42. Marik PE, Varon J. Sepsis. In: Irwin RS, Cerra FB, Rippe JM, eds. Intensive care medicine, 4th ed. Philadelphia: Lippincott-Raven, 1999:2031-2044
43. Horne M. Hemorrhagic and thrombotic disorders. In: Parrillo JE, ed. Current therapy in critical care medicine. St. Louis: Mosby Year Book, 1997:357-361
44. Silverman H, Tuma P. Gastric tonometry in patients with sepsis: effects of dobutamine infusion and packed red blood cell transfusions. Chest 1992;102:184-188
45. Emerson TE Jr, Fournel MA, Redens TB, et al. Efficacy of antithrombin III supplementation in animal models of fulminant Escherichia coli endotoxemia or bacteremia. Am J Med 1989;87:S27-S33
46. Lechner K, Kryle PA. Antithrombin III concentrates: are they clinically useful? Thromb Haemost 1995;73:340-348
47. Jochum M. Influence of high dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation. Semin Hematol 1995;32(suppl 2): 19-32
48. Baudo F, Caimi TM, deCataldo F, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/ or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 1998; 24:336-342
49. Bick RL. Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment, and assessment of therapeutic response. Semin Thromb Hemost 1996;22: 69-88
50. Feinstein D. Treatment of disseminated intravascular coagulation. Semin Thromb Hemost 1988;14:351-362
51. Sack GH, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic and therapeutic features. Medicine 1977;56:1-37
52. Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79:543-553
53. Naeye RL. Thrombotic state after a hemorrhagic diathesis, a possible complication of therapy with epsilon-aminocaproic acid. Blood 1962;19:694-701
54. Carey MJ, Rodgers GM. Disseminated intravascular coagulation: clinical and laboratory aspects. Am J Hematol 1998;59: 65-73
55. Umeki S, Adachi M, Watanabe M, et al. Gabexate as a therapy for disseminated intravascular coagulation. Arch Intern Med 1988;148:1409-1412
56. Okamura T, Niho Y, Itoga T, et al. Treatment of disseminated intravascular coagulation and its prodromal stage with gabexate mesilate (FOY): a multi-center trial. Acta Haematol 1993;90:120-124
57. Svartholm E, Haaglund U, Ljunberg G, et al. Influence of aprotinin, a proteinase inhibitor, on porcine E. coli shock. Studies of coagulation, fibrinolytic and hemodynamic response. Acta Chir Scand 1989;155:7-13
58. Sundt TM, Kouchoukos NT, Saffitz JE, et al. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 1993;55: 1418-1424
59. Baja MS, Bajaj SP. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost 1997;78:471-477
60. Creasey AA, Chang AC, Feigen L, et al. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993;91:2850-2856
61. Drollinger AG, Netser JC, Rodgers GM. Dithiocarbamates ameliorate the effects of endotoxin in a rabbit model of disseminated intravascular coagulation (DIC). J Invest Med 1998;46:78A
62. Uchiba M, Okajima K, Murakami K, et al. Effect of human urinary thrombomodulin on endotoxin-induced intravascular coagulation and pulmonary vascular injury in rats. Am J Hematol 1997;54:118-123